Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis

Johnny Kao, Jonathan Timmins, Junko Ozao-Choy, Stuart Packer

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

There is considerable interest in deploying stereotactic body radiotherapy in combination with immune therapy for patients with extracranial oligometastases. In addition to angiogenesis inhibition, sunitinib appears to mediate antitumor immunity through effects on circulating monocytic cells. The current study investigated the effects of combined sunitinib and stereotactic radiotherapy on hematopoiesis. As part of a phase I/II clinical trial utilizing concurrent sunitinib (25-50 mg on days 1-28) and image-guided radiation therapy (40-50 Gy in 10 fractions starting on days 8-19) for patients with metastatic cancer, the complete blood count, platelet count and automatic differential were performed pretreatment and on days 8 and 19. On average, sunitinib monotherapy for 7 days resulted in a 33% decrease in monocytes and an 18% decrease in neutrophils (P

Original languageEnglish (US)
Pages (from-to)2139-2144
Number of pages6
JournalOncology Letters
Volume12
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Keywords

  • Hematopoiesis
  • Monocytes
  • Stereotactic radiotherapy
  • Sunitinib
  • Tumor immunology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis'. Together they form a unique fingerprint.

  • Cite this